Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms |
Target |
Mechanism αvβ3 modulators(Integrin alpha-V/beta-3 modulators), SPECT(Single-photon emission-computed tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Phase 3 | CN | 30 Jul 2019 | |
Lymphatic Metastasis | Phase 3 | CN | 30 Jul 2019 | |
Lymphatic Metastasis | Phase 3 | CN | 30 Jul 2019 | |
Rheumatoid Arthritis | Phase 3 | CN | 01 Nov 2015 | |
Neoplasms | Phase 1 | CN | - | 02 Jan 2019 |
Lymphatic Metastasis | Discovery | CN | 30 Jul 2019 | |
Esophageal Carcinoma | Discovery | CN | 01 Oct 2015 |
Not Applicable | - | 99mTc-3PRGD2 | (cfaftukodo) = ovahmdhctc mxyvigydzo (kuupvjnsmi ) View more | - | 01 Aug 2015 | ||
99mTc-3PRGD2 | (cfaftukodo) = qqjxqdwdhu mxyvigydzo (kuupvjnsmi ) View more | ||||||
Early Phase 1 | 44 | swjbertpvf(qeantpcjwy) = soffgbsuzd ujgbjygqjf (cndbrfyfkk ) View more | - | 01 Jan 2014 | |||
99mTc-MDP | swjbertpvf(qeantpcjwy) = dikldhkztr ujgbjygqjf (cndbrfyfkk ) View more | ||||||
Not Applicable | 30 | (99Tcm-3PRGD2 SPECT/CT) | (hctvchsysy) = ttrggsyrcr dgoxzgiqzn (lpeshdjfxt, 74.8 - 92.1) View more | - | 21 Sep 2022 |